Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

  • Till Koch, Christine Dahlke, Anahita Fathi, Alexandra Kupke, Verena Krähling, Nisreen M A Okba, Sandro Halwe, Cornelius Rohde, Markus Eickmann, Asisa Volz, Thomas Hesterkamp, Alen Jambrecina, Saskia Borregaard, My L Ly, Madeleine E Zinser, Etienne Bartels, Joseph S H Poetsch, Reza Neumann, Robert Fux, Stefan Schmiedel, Ansgar W Lohse, Bart L Haagmans, Gerd Sutter, Stephan Becker, Marylyn M Addo
  • The Lancet Infectious Diseases, April 2020, Elsevier
  • DOI: 10.1016/s1473-3099(20)30248-6

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s1473-3099(20)30248-6

The following have contributed to this page: Dr Bart L. Haagmans